Cellbion Co

Cellbion Co Intangible Assets

The Intangible Assets of Cellbion Co (308430.KQ) as of Oct 21, 2026 is 634.80 M KRW. In the previous year, Intangible Assets was 688.93 M KRW — a change of -7.86% (lower).

Intangible Assets

634.80 MKRW

YoY

-7.86%

Last updated:

Intangible Assets of Cellbion Co is 2024 634.80 M KRW. Intangible Assets of Cellbion Co was 2023 688.93 M KRW. It decreases by -7.86% lower compared to the previous year.

The Cellbion Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2022
645.92 M KRW
Jan 1, 2023
688.93 M KRW
Jan 1, 2024
634.80 M KRW
The Cellbion Co Intangible Assets history
YEARIntangible AssetsYoY
634.80 MKRW-7.86%
688.93 MKRW+6.66%
645.92 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

Intangible Assets of Cellbion Co is 634.80 M KRW in 2024.

Intangible Assets of Cellbion Co changed from 688.93 M KRW to 634.80 M KRW, representing a -7.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Cellbion Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Cellbion Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Cellbion Co